A comparative phase 1 clinical trial to identify anti-infective mechanisms of Vitamin D in people with HIV infection

AIDS

Volumn 29, Issue 10, 2015, Pages 1127-1135

  Lachmann, Raskit ^a   Bevan, Margaret A ^a   Kim, Sangmi ^a   Patel, Nishma ^a   Hawrylowicz, Catherine ^a   Vyakarnam, Annapurna ^a,b   Peters, Barry S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Cathelicidin; CCL4; CD4+ T cells; HIV; MIP 1b; Regulatory T cells; Vitamin D

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CALCIFEDIOL; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COLECALCIFEROL; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR; VITAMIN D;

ADJUVANT THERAPY; ADULT; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CD38+ T CELL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; T LYMPHOCYTE; TREATMENT RESPONSE; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; CLINICAL TRIAL; COMPARATIVE STUDY; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTI-INFECTIVE AGENTS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN D;

EID: 84942879673     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000666     Document Type: Article

References (27)

1. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; 384: 258-271.
2. Chun RF, Liu PT, Modlin RL, Adams JS, Hewison M. Impact of vitamin D on immune function: lessons learned from genomewide analysis. Front Physiol 2014; 5:151.
3. Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, et al., EuroSIDA Study Group. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011; 25:1305-1315.
4. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-A review of recent evidence. Autoimmun Rev 2013; 12:976-989.
5. Hossein-Nezhad A, Spira A, Holick MF. Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One 2013; 8:e58725.
6. Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. J Steroid Biochem Mol Biol 2013; 136:321-329.
7. Urry Z, Chambers ES, Xystrakis E, Dimeloe S, Richards DF, Gabrysová L, et al. The role of 1a,25-dihydroxyvitamin D3 and cytokines in the promotion of distinct Foxp3R and IL-10R CD4R T-cells. Eur J Immunol 2012; 42:2697-2708.
8. Cantorna MT, Waddell A. The vitamin D receptor turns off chronically activated T-cells. Ann N Y Acad Sci 2014; 1317: 70-75.
9. von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T-cell antigen receptor signaling and activation of human T-cells. Nat Immunol 2010; 11:344-349.
10. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A 2012; 109:15449-15454.
11. Pinzone MR, Di Rosa M, Malaguarnera M, Madeddu G, Focá E, Ceccarelli G, et al. Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci 2013; 17:1218-1232.
12. Ansemant T, Mahy S, Piroth C, Ornetti P, Ewing S, Guilland JC, et al. Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients. BMC Infect Dis 2013; 13:7.
13. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN) Investigators. Low vitamin Damong HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52:396-405.
14. Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther 2010; 6405:7-40.
15. Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, Post FA. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24: 1923-1928.
16. Giacomet V, Vigano A, Manfredini V, Cerini C, Bedogni G, Mora S, et al. Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. HIV Clin Trials 2013; 14:51-60.
17. Aziz M, Livak B, Burke-Miller J, French AL, Glesby MJ, Sharma A, et al. Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART. AIDS 2013; 27:573-578.
18. Moreno-Fernandez ME, Presicce P, Chougnet CA. Homeostasis and function of regulatory T-cells in HIV/SIV infection. J Virol 2012; 86:10262-10269.
19. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; 384(9939):258-271.
20. Wang G, Watson KM, Buckheit RW Jr. Antihuman immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins. Antimicrob Agents Chemother 2008; 52:3438-3440.
21. Wang G, Mishra B, Epand RF, Epand RM. High-quality 3D structures shine light on antibacterial, antibiofilm and antiviral activities of human cathelicidin LL-37 and its fragments. Biochim Biophys Acta 2014; 1838:2160-2172.
22. Makedonas G, Betts MR. Polyfunctional analysis of human T-cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol 2006; 28:209-219.
23. Geldmacher C, Koup RA. Pathogen-specific T-cell depletion and reactivation of opportunistic pathogens in HIV infection. Trends Immunol 2012; 33:207-214.
24. Eyeson J, King D, Boaz MJ, Sefia E, Tomkins S, Waters A, et al. Evidence for Gag p24-specific CD4 T-cells with reduced susceptibility to R5 HIV-1 infection in a UK cohort of HIVexposed-seronegative subjects. AIDS 2003; 17:2299-2311.
25. Boesecke C, Pett SL. Clinical studies with chemokine receptor-5 (CCR5)-inhibitors. Curr Opin HIV AIDS 2012; 7:456-462.
26. O'Kelly J, Hisatake J, Hisatake Y, Bishop J, Norman A, Koeffler HP. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 2002; 109:1091-1099.
27. Campbell GR, Spector SA. Toll-like receptor 8 ligands activate a vitamin D mediated autophagic response that inhibits human immunodeficiency virus type 1. PLoS Pathog 2012; 8:e1003017.